Peptidyl-Prolyl Cis/Trans Isomerase Pin1 and Alzheimer’s Disease

Long Wang†, Ying Zhou†‡, Dongmei Chen† and Tae Ho Lee*†

† Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China, ‡ Key Laboratory of Brain Aging and Neurodegenerative Diseases of Fujian Provincial Universities and Colleges, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China

Alzheimer’s disease (AD) is the most common cause of dementia with cognitive decline. The neuropathology of AD is characterized by intracellular aggregation of neurofibrillary tangles consisting of hyperphosphorylated tau and extracellular deposition of senile plaques composed of beta-amyloid peptides derived from amyloid precursor protein (APP). The peptidyl-prolyl cis/trans isomerase Pin1 binds to phosphorylated serine or threonine residues preceding proline and regulates the biological functions of its substrates. Although Pin1 is tightly regulated under physiological conditions, Pin1 deregulation in the brain contributes to the development of neurodegenerative diseases, including AD. In this review, we discuss the expression and regulatory mechanisms of Pin1 in AD. We also focus on the molecular mechanisms by which Pin1 controls two major proteins, tau and APP, after phosphorylation and their signaling cascades. Moreover, the major impact of Pin1 deregulation on the progression of AD in animal models is discussed. This information will lead to a better understanding of Pin1 signaling pathways in the brain and may provide therapeutic options for the treatment of AD.

Keywords: Alzheimer’s disease, amyloid precursor protein (APP), Pin1, phosphorylation, tau

INTRODUCTION

Alzheimer’s disease (AD) is the most common form of dementia, accounting for 50–75% of all cases, and presents as a series of cognitive or behavioral symptoms including decline in memory (Mckhann et al., 2011; Lane et al., 2018; Alzheimer’s Association, 2019). The progression of AD may drive or be exacerbated by various systemic abnormalities, such as abnormalities in systemic immunity, metabolic disorders, cardiovascular disease, and sleep disorders (Wang et al., 2017). Approximately 50 million people worldwide currently suffer from dementia, and this number is expected to triple in the next three decades due to the increasing number of aging people (Lane et al., 2018). The neuropathological hallmarks of AD are the intracellular aggregation of neurofibrillary tangles (NFTs) containing paired helical filaments (PHFs) consisting of hyperphosphorylated tau protein and the extracellular deposition of senile plaques (SPs) composed of beta-amyloid (Aβ) peptides derived from amyloid precursor protein (APP) (Hardy and Selkoe, 2002;
Binder et al., 2005; Goedert and Spillantini, 2006; Roberson and Mucke, 2006; Ballatore et al., 2007; Ittner and Gotz, 2011). However, the molecular link and mechanisms underlying the pathogenesis of AD are not fully understood. Therefore, understanding the early disease mechanisms responsible for neurodegeneration in AD is critical for identifying proper diagnostic approaches and new effective therapeutic targets.

Protein phosphorylation is one of the major post-translational modifications and is involved in diverse cellular processes regulating numerous physiological and pathological processes (Cohen, 1982; Nestler and Greengard, 1983; Oliveira et al., 2017; Butterfield, 2019). In particular, serine or threonine residues preceding proline (S/T-P) are the most frequently phosphorylated motifs in AD (Lu et al., 2002, 2003; Lu, 2004; Lu and Zhou, 2007; Iqbal et al., 2016). Interestingly, due to its unique five-carboxyl ring structure, proline is able to present as two strikingly distinct conformations, *cis* and *trans* (Lu et al., 1996, 1999a, b; Ranganathan et al., 1997; Yaffe et al., 1997; Wulf et al., 2005; Lu et al., 2007; Lu and Zhou, 2007). The peptide bond dihedral angle ω of proline residue adopts either about 0° (cis conformation) or about 180° (trans conformation), which plays critical roles in the rate-determining steps of protein folding, thus controlling the biological activity of proteins and their cellular progression (Wedemeyer et al., 2002; Andreotti, 2003; Fischer and Aumuller, 2003; Cortes-Hernandez and Dominguez-Ramirez, 2017). The spontaneous interconversion of cis/trans isomerization occurs slowly but can be catalyzed by a number of peptidyl-prolyl cis/trans isomerases (PPIases), such as cyclophilins, FK506-binding proteins (FKBPs), and parvulintype PPIases (Fischer and Aumuller, 2003; Lu and Zhou, 2007). Cyclophilins and FKBPs not only belong to immunophilins which are cellular targets for the immunosuppressive drugs, but also have relationships with tau-related and Aβ pathology (Blair et al., 2015). Cyclophilin D is one of the most unique and well-studied cyclophilins, and cyclophilin D deficiency can protect neurons from Aβ- and oxidative stress-induced toxicity (Du et al., 2008, 2014; Guo et al., 2013). FKBPs with a molecular mass of ∼52 kDa (FKBP52) is one of the most well-studied FKBPs, and FKBP52 has been shown to be highly expressed in neurons and abnormally low in AD brains (Giusti et al., 2012, 2014, 2015). Nevertheless, the phosphorylation of an S/T-P motif further slows the spontaneous isomerization rate and renders the peptide bond against the catalytic action of known PPIases (Wulf et al., 2005; Lu and Zhou, 2007). Thus, the important discovery of Pin1 has shed light on the significance of this intrinsic conformational switch in human physiology and pathology.

Pin1 (protein interacting with NIMA (never in mitosis A)-1) was originally identified in a yeast genetic and biochemical screen for proteins involved in mitotic regulation (Lu et al., 1996, 2002). The yeast Pin1 homolog Ess1 has been found to be the only enzyme being essential for survival among 13 PPIases since its discovery (Hanes et al., 1989; Lu, 2004). The human Pin1 has 163 amino acids with a molecular mass of 18 kDa, containing an N-terminal WW domain (residues 1–39) characterized by two invariant tryptophans and a C-terminal PPIase domain (residues 50–163) which shares little similarity with cyclophilins and FKBPs (Lu et al., 1996; Ranganathan et al., 1997). Pin1 is a unique and conserved PPIase that binds to specific phosphorylated proline-directed serine or threonine (pS/T-P) motifs and catalyzes the *cis/trans* isomerization of peptidyl-prolyl peptide bonds (Lu et al., 1996, 1999b; Ranganathan et al., 1997; Yaffe et al., 1997; Schutkowski et al., 1998; Shen et al., 1998). The unique substrate specificity of Pin1 results from the organization of active site residues (Ranganathan et al., 1997; Lu et al., 2002). Specifically, the residues L122, M130, and F134 form a hydrophobic binding pocket for the substrate proline, and the cluster sequestering K63, R68, and R69 forms a positive charged phosphate binding loop which either interacts with a bound sulfate ion or facilitates binding to the pS/T-P motif (Ranganathan et al., 1997; Behrens et al., 2007; Lee and Liou, 2018). Further studies revealed that mutation of R68 and R69 could abolish the striking phosphorylation-specificity completely but barely affect the basic enzymatic activity (Yaffe et al., 1997; Zhou et al., 2000; Lu et al., 2002).

In addition, the WW domain has been shown to target Pin1 to the substrates since it has a higher affinity to phosphorylated peptides as compared to the PPIase domain (Lu et al., 1999b; Smet et al., 2005). This Pin1-mediated conformational change of its substrates regulates numerous cellular processes, such as cell-cycle progression, cellular stress responses, development, neuronal function, immune responses, and cell death (Zhou et al., 1999a; Lu and Zhou, 2007). Notably, Pin1 deregulation is implicated in age-dependent human diseases, including cancer and AD (Lu and Zhou, 2007; Lee et al., 2011b; Zhou and Lu, 2016). Pin1 activity and expression are significantly inhibited in human AD brains and highly increased in diverse types of cancers, indicating that Pin1 might have important roles in both proliferation and degeneration (Lu et al., 1999a; Liou et al., 2003; Butterfield et al., 2006; Lu and Zhou, 2007; Lee et al., 2011b; Driver et al., 2012; Zhou and Lu, 2016; Chen et al., 2020).

This review focuses on the deregulation of Pin1 in AD brains, the currently understood mechanisms of tau hyperphosphorylation and APP processing associated with Pin1, and the major impact of Pin1 deregulation on AD development. This advanced understanding of the involvement of the Pin1 signaling pathway in phosphorylation will support Pin1 as a novel potential diagnostic and therapeutic target.

**REGULATION OF PIN1 IN AD**

**Pin1 Expression in AD**

The significantly different levels of soluble and functional Pin1 between the brain samples of patients with AD and the control brain samples from age-matched normal subjects suggest a possible protective role of Pin1 against AD. A large amount of soluble Pin1 is dramatically depleted and sequestrated in NFTs in the human AD brain but not in age-matched normal brains (Lu et al., 1999a). Pin1 expression has been further examined in the human hippocampus, a brain region that is particularly vulnerable to AD damage at early stages (Liou et al., 2003; Mu and Gage, 2011). In the hippocampus of normally aged brain samples, the expression of Pin1 in the CA1 region and subiculum
is relatively lower than that in the CA4, CA3, and CA2 regions and presubiculum (Liou et al., 2003; Lu et al., 2003). Notably, in AD brains, NFTs predominantly occur in the CA1 region and subiculum, consistent with the finding that these subregions are prone to pyramidal neuron loss in AD (Davies et al., 1992; Liou et al., 2003). Indeed, among a randomly selected pool of 1,000 pyramidal neurons in AD, 96% of pyramidal neurons with higher expression of Pin1 seem to avoid tau-related pathology, while 71% of neurons with lower expression of Pin1 are vulnerable to NFT formation (Liou et al., 2003). On the contrary, some groups also reported that Pin1 was localized to granular vesicles but not to tau aggregates in AD (Holzer et al., 2002; Ramakrishnan et al., 2003; Dakson et al., 2011; Ando et al., 2013). Recently, according to the hippocampal gene expression profiles of patients from three distinct age groups, the expression of Pin1 is decreased slightly in the aging group but is dramatically decreased in the AD group compared with the young group (Lanke et al., 2018). These results suggest that reduced expression of Pin1 may contribute to the development of AD, including neurofibrillary degeneration.

**Pin1 Genetics in AD**

The apolipoprotein E (APOE) ε4 allele was the first definitive gene to be implicated in late-onset AD (LOAD) and is located on chromosome 19q13.2 (Corder et al., 1993; Huq et al., 2019; Yamazaki et al., 2019). Although the human Pin1 gene is located on the same chromosome, this locus has been identified as a novel LOAD locus and is independent of APOE (Wijmser et al., 2004). Currently, three single nucleotide polymorphisms (SNPs) in the promoter region of the Pin1 gene have been identified to investigate their correlations with AD, including rs2287839 (-5185 G/C), rs2233678 (-842 G/C), and rs2233679 (-667 T/C). All of Pin1 polymorphism studies were conducted using genomic DNA from blood cells between AD patients and age-matched normal subjects. The polymorphism rs2233678 results in decreased Pin1 levels and is associated with a significantly raised risk of developing AD (Segat et al., 2007). The polymorphism rs2287839 leads to increased Pin1 expression and is correlated with 3-year delayed onset of LOAD (Ma et al., 2012b). However, other groups showed that polymorphisms in the promoter of Pin1, rs2233678 and rs2233679, were not associated with increased LOAD risk (Lambert et al., 2006; Nowotny et al., 2007; Cao et al., 2013). Interestingly, rs2233678 and rs2233679 have also been shown to decrease Pin1 expression and are implicated in the decreased risk of breast cancer, lung cancer, and nasopharyngeal carcinoma (Han et al., 2010; Lu et al., 2011, 2013). Therefore, since the controversial results remain to be elucidated, further validation of large prospective studies is needed to verify the roles of Pin1 polymorphisms in AD. Recently, a highly pathogenic and novel somatic single nucleotide variation (SNV) in Pin1 has been found in the hippocampal formation (HIF) of an AD patient (Park et al., 2019). Since the T152M mutation is located in the C-terminal PPLase domain of Pin1, the mutation might attenuate the enzymatic activity of Pin1 and increase tau hyperphosphorylation (Park et al., 2019). However, the molecular mechanism by which the somatic mutation regulates Pin1 activity and whether T152M knockin mice show tau-related and Aβ pathology remain to be elucidated.

**Pin1 Post-translational Modification in AD**

Pin1 activity is regulated by post-translational modifications, including oxidation and phosphorylation, in AD. Neurons in the human brain are vulnerable to oxidative stress, and increased oxidative damage has been shown to be an early event in AD (Markesbery, 1997; Nunomura et al., 2001; Halliwell, 2006). Notably, Pin1 is modified by oxidation, leading to the loss of its activity in the hippocampus in AD (Butterfield et al., 2006; Sultana et al., 2006). Besides, oxidized Pin1 may be recognized by the ubiquitinylation system, giving rise to the polyubiquitination (Tramutola et al., 2018). By employing antibodies specifically recognizing oxidized C113 of Pin1, Pin1 oxidation on C113 has been identified to inactivate the catalytic activity of Pin1, and C113-oxidized Pin1 is elevated in human AD brains compared with age-matched controls (Chen et al., 2015). It is possible that an increased percentage of C113-oxidized Pin1 in response to oxidative stress may result in the inhibition of enzymatic activity and reduction of Pin1 levels. The loss of Pin1 activity induced by oxidative stress may also result in the loss of synaptic plasticity, which is the structural basis for memory impairment in AD (Xu et al., 2017). These results suggest that the protective roles of Pin1 may be attenuated by a variety of reactive oxygen species, which are common in human AD brains.

Recently, death-associated protein kinase 1 (DAPK1) has been found to play essential roles in neuronal cell death and various neurodegenerative diseases, including AD (Chen et al., 2019; Kim et al., 2019). Importantly, DAPK1 is capable of phosphorylating Pin1 at S71 in the PPLase domain, thus inhibiting its nuclear localization, prolyl isomerase activity, and cellular function (Lee et al., 2011a,b). DAPK1 dramatically increases tau protein stability and hyperphosphorylation at multiple AD-related sites, which is mediated by the inhibition of Pin1 activity by phosphorylation (Kim et al., 2014). DAPK1 phosphorylates and activates N-myc downstream-regulated gene 2 (NDRG2), resulting in increased tau phosphorylation via a reduction in Pin1 expression (Rong et al., 2017; You et al., 2017). In summary, the existence of Pin1 in the normal brain may have certain protective functions against AD, as decreased expression or declined activity of Pin1 may be attenuated by a variety of reactive oxygen species, which are common in human AD brains.

**PIN1 AND TAU-RELATED PATHOLOGY**

The intracellular aggregation of NFTs containing PHFs made of hyperphosphorylated tau is one of the neuropathological hallmarks of AD (Geschwind, 2003; Binder et al., 2005; Goedert and Spillantini, 2006; Roberson and Mucke, 2006; Ballatore et al., 2007). Compared with Aβ pathology, which may play a critical role in AD pathogenesis, the prevalence of NFTs has a strong correlation with the severity of cognitive impairment, indicating that tau-related pathology may indicate the status of cognitive deficits and dementia (Nelson et al., 2012). Encoded by a single gene, MAPT, located on human chromosome 17, tau is a type of microtubule-associated protein and is expressed predominantly in the brain (Lee et al., 1989;
It is well-established that the physiological function of tau is to maintain microtubule-related functions, such as microtubule assembly and axonal transportation, and the abnormal hyperphosphorylation of tau inhibits normal microtubule functions and alters tau protein stability (Drubin and Kirschner, 1986; Bramblett et al., 1993; Alonso et al., 1994; Petrucelli et al., 2004; Shimura et al., 2004; Stoothoff and Johnson, 2005; Poppek et al., 2006). Specifically, abnormally phosphorylated tau is detached from microtubules and disrupts microtubule integrity (Iqbal et al., 2009, 2016). Hyperphosphorylated tau, but not normal tau, is a component of PHF-forming insoluble aggregates and further becomes NFTs (Lee et al., 1991; Goedert et al., 1992; Matsuo et al., 1994). These results indicate that the phosphorylation of tau is essential for the development of tau-related pathology.

The phosphorylation of T231 (pT231), among a number of tau phosphorylation sites, appears to be the first detectable event during AD pretangle formation (Luna-Munoz et al., 2007). pT231 may play a critical role in regulating the conformation and misfolding process of tau (Lee et al., 2011b; Iqbal et al., 2016). Notably, Pin1 colocalizes with phosphorylated tau, directly binds to pT231-tau, and can restore its biological activity by promoting tau dephosphorylation and increase microtubule assembly (Lu et al., 1999a, 2003; Ramakrishnan et al., 2003; Lu, 2004). Pin1 facilitates tau dephosphorylation through the proline-directed phosphatase PP2A, which has conformational specificity and dephosphorylates only the trans pS/T-P motif (Zhou et al., 2000). Pin1 has been found to bind PHFs and be trapped in tangles in the AD brain, resulting in the depletion of soluble Pin1 (Lu et al., 1999a). A recent in vitro study showed that reduced Pin1 expression led to the increase of pT231-tau levels (Park et al., 2019). Pin1 has been shown to accelerate the cis to trans isomerization of pT231-tau, restore its function, and maintain tau levels via proteasome-dependent proteolytic pathway (Poppek et al., 2006; Lim et al., 2008). However, Pin1 has no effect on T231A mutant tau (Lim et al., 2008; Nakamura et al., 2012). Interestingly, when hippocampal cultured neurons are exposed to Aβ42 oligomers, Pin1 can be activated to dephosphorylate pT231-tau mediated by PP2A (Bulbarelli et al., 2009). Notably, studies have showed that microtubule assembly can be significantly increased by unphosphorylated wild-type tau, but not phosphorylated tau which can be restored by PP2A, while the phosphorylated T231A tau is still able to promote microtubule assembly and this ability is not affected by Pin1, suggesting that T231 phosphorylation is critical for Pin1 to maintain microtubule function of tau (Nakamura et al., 2012). Therefore, tau hyperphosphorylation might induce tau aggregation which further sequestrates Pin1, thereby preventing pT231-tau dephosphorylation mediated by PP2A (Figure 1). However, other studies have questioned the specificity of Pin1 targeting site, as they revealed that Pin1 recognized other pS/T-P sites such as pT212 and pS235 motifs in full-length tau, which were the preferred substrates over pT231 motif (Smet et al., 2004, 2005; Landrieu et al., 2006; Kimura et al., 2013; Eichner et al., 2016). Besides, other studies also indicated that Pin1 did not regulate the microtubule function of phosphorylated tau (Lippens et al., 2007; Landrieu et al., 2010, 2011; Kutter et al., 2016; Lu et al., 2016; Rogals et al., 2016). Therefore, the specificity of Pin1 targeting sites of tau and the regulatory function of Pin1 toward phosphorylated tau raise other possibilities which need further investigation.

Recently, the Lu laboratory developed conformation-specific cis and trans polyclonal and monoclonal pT231-tau antibodies (Nakamura et al., 2012; Kondo et al., 2015). Specifically, cis pT231-tau appears to be more responsible for resistance to tau dephosphorylation and degradation, the disruption of microtubule structure, and vulnerability toward aggregation, and Pin1 catalyzes the isomerization of pT231-tau from cis to trans, restoring its ability to bind microtubules (Lu et al., 1999a, 2003; Nakamura et al., 2012; Albayram et al., 2016, 2018). Indeed, cis pT231-tau, but not trans pT231-tau, is significantly increased and localized to dystrophic neurites in human mild cognitive impairment (MCI) and AD brains (Nakamura et al., 2012). Furthermore, cis pT231-tau, but not trans pT231-tau, strongly correlates with neurofibrillary degeneration, which is associated with decreased Pin1 levels in the AD hippocampus, in accord with the binding of Pin1 to PHFs leading to the depletion of soluble Pin1 (Lu et al., 1999a; Nakamura et al., 2012). In addition, cis pT231-tau is dramatically induced, facilitates the disruption of axonal microtubules and organelle transport, and finally leads to neuronal apoptosis under neuronal stress (Kondo et al., 2015). Therefore, the neurotoxic cis pT231-tau may function as
a critical driver of neurodegeneration, as it can spread among neurons in a prion-like fashion (Kondo et al., 2015; Albayram et al., 2018). In tau-overexpressing mice, while trans pT231-tau is barely detected in sarkosyl-insoluble fractions, cis pT231-tau levels are robustly increased in insoluble fractions in the brain (Nakamura et al., 2012). Interestingly, cis pT231-tau has been shown to be a major early driver of traumatic brain injury (Kondo et al., 2015; Albyramp et al., 2017). These results suggest that the Pin1-regulated isomerization of the cis to trans conformations of phosphorylated tau is a key mechanism to protect against tau-related pathology. Nevertheless, the cis pT231-tau antibody raised against a peptide containing a chemically modified proline instead of a native cis-proline has also been questioned, and it is suggested that the specific pT231-P32 bond in phosphorylated tau be majorly in the trans conformation (Shih et al., 2012; Ahuja et al., 2016; Lippens et al., 2016).

Thus, Pin1 may maintain normal tau functions through the conformational change of pT231-tau, but its deregulation leads to tau-related pathology during AD development. However, Pin1 acts on different phosphorylation sites of tau and has opposite results of tau function. This discrepancy may be due to the different characteristics of the diverse physiological and pathological conditions. Therefore, more evidence is needed to clarify the role of Pin1 in phosphorylated tau and its function.

**PIN1 AND APP PROCESSING**

The extracellular deposition of SPs composed of Aβ peptide derived from APP is another neuropathological hallmark of AD (Hardy and Selkoe, 2002). The human APP gene is located on chromosome 21 and encodes a type I transmembrane protein that plays important roles in neuronal growth, survival, and repair (Thinakaran and Koo, 2008). Upon synthesis in the endoplasmic reticulum, APP undergoes trafficking through the Golgi/trans-Golgi network (TGN) toward the plasma membrane, where it accumulates and internalizes to the endosomes (Selkoe et al., 1996; Thinakaran and Koo, 2008; Pastorino et al., 2012). APP is processed by two different proteolytic processes, the non-amyloidogenic pathway and amyloidogenic pathway (Koo and Nunan, 2002; Vetrivel and Thinakaran, 2006). In the non-amyloidogenic processing pathway, APP is cleaved by α-secretase at a site within the sequence of Aβ at the plasma membrane, generating soluble extracellular sAPPα with neurotrophic properties and a C-terminal fragment, C83; C83 is further cleaved by γ-secretase to generate the APP intracellular domain (AICD) and Aβ, reducing Aβ production, while the inhibition of γ-secretase increases Aβ production, while the inhibition of GSK3β increases Aβ production, while the inhibition of GSK3β contributes to major neurological disorders, including both familial and sporadic AD (Hooper et al., 2008; Peineau et al., 2008). The hyperactivity of GSK3β increases Aβ production, while the inhibition of GSK3β reduces plaques in vitro and in vivo (Lovestone et al., 1994; Flaherty et al., 2000; Engel et al., 2006; Hurtado et al., 2012). Ma and colleagues showed that Pin1 directly binds to the phosphorylated T330-P motif in GSK3β and inhibits its kinase activity in vitro and in vivo (Ma et al., 2012a). Among them, GSK3β is a widely expressed proline-directed serine/threonine kinase that is implicated in a number of physiological processes in the nervous system (Jiang et al., 2005; Yoshimura et al., 2005; Castano et al., 2010). The aberrant regulation of GSK3β contributes to major neurological disorders, including both familial and sporadic AD (Hooper et al., 2008; Peineau et al., 2008). The hyperactivity of GSK3β increases Aβ production, while the inhibition of GSK3β reduces plaques in vitro and in vivo (Lovestone et al., 1994; Flaherty et al., 2000; Engel et al., 2006; Hurtado et al., 2012). Ma and colleagues showed that Pin1 directly binds to the phosphorylated T330-P motif in GSK3β and inhibits its kinase activity in vitro and in vivo (Ma et al., 2012a). The suppression of Pin1 causes GSK3β activation, leading to increased levels of T668-phosphorylated APP and amyloidogenic APP processing. In addition, Pin1 promotes APP degradation by binding to the phosphorylated T330-P motif of GSK3β (Ma et al., 2012a; Xiong et al., 2013). Thus, Pin1 promotes APP protein turnover by inhibiting GSK3β activity, suggesting a novel neuroprotective role of Pin1 against Aβ pathology. However, contrasting results showed that in the Pin1-deficient mice Aβ was lower and Pin1 promoted Aβ production in vitro (Akiyama et al., 2005). The discrepancy might due to the usage of β-cleaved carboxy-terminal fragment C99 instead of full-length APP and detection of the mouse brain at an unspecified age. Thus, in healthy neurons, sufficient levels of APP processing and Aβ generation are regulated by the phosphorylation of the intracellular C-terminal fragment (Pastorino and Lu, 2005; Suzuki and Nakaya, 2008). Notably, the phosphorylation of APP at the T668-P motif is increased in the brains of AD patients compared with those of age-matched controls, facilitating the amyloidogenic processing pathway and Aβ generation (Lee et al., 2003). Importantly, Pin1 binds to APP specifically on the phosphorylated T668-P motif in vitro and in vivo (Pastorino et al., 2006). The binding of Pin1 to phosphorylated T668-P accelerates its isomerization from cis to trans by over 1,000-fold, as visualized by NMR spectroscopy (Ramelot et al., 2000; Ramelot and Nicholson, 2001; Pastorino et al., 2006). The overexpression of Pin1 significantly decreases Aβ secretion in vitro, while Pin1 ablation dramatically increases insoluble Aβ42 secretion in cell models and mouse models in an age-dependent manner (Pastorino et al., 2006). Pin1 is colocalized with APP at the plasma membrane and in clathrin-coated vesicles rather than endosomes, and Pin1 inhibition leads to reduced APP levels at the plasma membrane (Pastorino et al., 2006, 2012). Pin1 influences the levels of Fe65, which can interact with APP and facilitate amyloidogenic APP processing (Pastorino et al., 2012, 2013). Thus, Pin1 isomerizes APP to the trans conformation, controls the intracellular localization and internalization of APP, modules AICD in a Fe65-dependent manner, and thus exerts a protective function against Aβ pathology, indicating that the Pin1-regulated prolyl isomerization of APP plays a key role in regulating Aβ pathology. A number of protein kinases responsible for phosphorylating APP at the T668-P motif are abnormally elevated in the AD brain, such as GSK3β, SAPK1b/JNK3, Cdc2, and Cdk5 (Zhou et al., 2000; Lee et al., 2003, 2011b; Lu and Zhou, 2007; Ma et al., 2012a). Among them, GSK3β is a widely expressed proline-directed serine/threonine kinase that is implicated in a number of physiological processes in the nervous system (Jiang et al., 2005; Yoshimura et al., 2005; Castano et al., 2010). The aberrant regulation of GSK3β contributes to major neurological disorders, including both familial and sporadic AD (Hooper et al., 2008; Peineau et al., 2008). The hyperactivity of GSK3β increases Aβ production, while the inhibition of GSK3β reduces plaques in vitro and in vivo (Lovestone et al., 1994; Flaherty et al., 2000; Engel et al., 2006; Hurtado et al., 2012). Ma and colleagues showed that Pin1 directly binds to the phosphorylated T330-P motif in GSK3β and inhibits its kinase activity in vitro and in vivo (Ma et al., 2012a). The suppression of Pin1 causes GSK3β activation, leading to increased levels of T668-phosphorylated APP and amyloidogenic APP processing. In addition, Pin1 promotes APP degradation by binding to the phosphorylated T330-P motif of GSK3β (Ma et al., 2012a; Xiong et al., 2013). Thus, Pin1 promotes APP protein turnover by inhibiting GSK3β activity, suggesting a novel neuroprotective role of Pin1 against Aβ pathology. However, contrasting results showed that in the Pin1-deficient mice Aβ was lower and Pin1 promoted Aβ production in vitro (Akiyama et al., 2005). The discrepancy might due to the usage of β-cleaved carboxy-terminal fragment C99 instead of full-length APP and detection of the mouse brain at an unspecified age. Thus, in healthy neurons, sufficient levels of...
Pin1 promote the non-amyloidogenic processing pathway of APP and its turnover, reducing Aβ secretion. However, when Pin1 expression is reduced or its activity is inhibited, amyloidogenic APP processing is increased, resulting in Aβ production and Aβ plaques in the AD brain (Figure 2).

PIN1 MOUSE MODELS OF AD

Animal models recapitulating the characteristics of AD are of vital importance not only for performing in vivo studies that explore molecular mechanisms but also for providing preclinical subjects for potential drug candidates. Due to research on familial forms of AD, transgenic mouse models have been developed and widely used (Games et al., 1995; Duff et al., 1996; Hsiao et al., 1996; Lewis et al., 2001; Gotz and Ittner, 2008). However, mutated tau and APP overexpression mice do not recapitulate all features of AD (Drummond and Wisniewski, 2017). Pin1 knockout (KO) mice were initially created to explore the function of Pin1 in mammalian cells, and they were viable and developed normally to adulthood (Fujimori et al., 1999). Importantly, Pin1 KO mice are the first mouse models to show both tau-related and Aβ pathology when a specific gene is deleted (Liou et al., 2003; Pastorino et al., 2006; Lu and Zhou, 2007; Lee et al., 2011b). Pin1 KO mice show tau hyperphosphorylation leading to age-dependent tau filament formation and NFT-like pathologies compared with their wild-type littermates (Liou et al., 2003). Pin1-KO mice also show neuronal loss and progressive age-dependent motor and behavioral deficits, such as abnormal limb-clasping reflexes, hunched posture, reduced mobility, and eye irritation (Liou et al., 2003). When neuron-specific Pin1 transgenic (Tg) mice are bred with wild-type tau Tg mice, Pin1 overexpression reduces tau hyperphosphorylation, NFT specific conformations, and aggregation (Lim et al., 2008). Surprisingly, in Tg mice overexpressing human P301L mutant tau, which causes frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pin1 KO drastically decreases the total tau levels and the hyperphosphorylation of tau, while Pin1-Tg promotes tau hyperphosphorylation, tau aggregation, and NFT conformation (Lim et al., 2008). This unexpected discrepancy was explained that the mutation might somehow render the pT231 motif in tau to be favored in the trans conformations (Lim et al., 2008). Therefore, Pin1 overexpression might accelerate the isomerization of the protective trans conformation to the pathogenic cis conformation, whereas Pin1 inhibition contributes to maintaining the trans conformation, facilitating P301L tau degradation (Lim et al., 2008). Since no tau mutations have been found in AD, tau-related pathology induced

![Figure 2](image_url)
by exogenous overexpression of mutant tau may be different from human AD in terms of molecular regulatory mechanisms. In addition, when Pin1 KO mice have been bred with tau-Tg mice, these mice exhibit increased cis pT231-tau, but decreased trans pT231-tau levels, supporting the Pin1-mediated suppression of tau-related neurodegeneration in mice (Nakamura et al., 2012).

Pin1 ablation in mice also affects APP processing in APP-overexpressing mouse brains (Pastorino et al., 2006). Compared with the wild-type littersmates, Pin1 KO mice exhibit increased levels of insoluble Aβ42, the major toxic species, at 15 months of age, but not at 6 months of age, suggesting that Pin1 KO promotes amyloidogenic APP processing in an age-dependent manner (Pastorino et al., 2006). Pin1 ablation in APP-Tg2576 mice significantly induces insoluble Aβ42 species and increases soluble APPβ levels at 6 months of age. These Aβ42 species are mainly localized to multivesicular bodies of neurons that experience Aβ plaque pathology (Pastorino et al., 2006). Thus, Pin1 is a unique protein, the deletion of which causes age-dependent tau-related and Aβ pathologies, suggesting evidence of a molecular link between tangles and plagues and a protective role of Pin1 against AD.

PIN1 IN DIAGNOSTIC AND THERAPEUTIC STRATEGIES FOR AD

Following a series of abnormal tau hyperphosphorylation that induces the formation of NFTs, pT231 appears to be the first detectable phosphorylation site of tau (Luna-Munoz et al., 2007). Due to the elevated sequestration of pT231-tau into the tangles and the decreased levels of pT231-tau that enter the cerebrospinal fluid (CSF), pT231-tau provides an early and specific biomarker of AD progression (Hampel et al., 2001; Spiegel et al., 2016). The assessment of pT231-tau in the CSF has been regarded as a good predictor of conversion from MCI to AD (Ewers et al., 2007). However, the presence of individual variations using pT231-tau might impede its application as a standardized test, whereas whether the existence of distinct forms (cis or trans) of pT231-tau helps to explain the variations remains to be investigated (Nakamura et al., 2012). Notably, cis and trans pT231-tau forms, which are regulated by Pin1, can be distinguished by recently developed conformation-specific antibodies (Nakamura et al., 2012; Kondo et al., 2015). Importantly, cis pT231-tau appears early in MCI, is pathologically more relevant, and contributes to AD (Nakamura et al., 2012). Current diagnostic approaches using CSF or positron emission tomography (PET) are either invasive or expensive, making it difficult to achieve early diagnosis using these approaches (Wang et al., 2017; Long and Holtzman, 2019). Commonly known markers used as diagnostic methods are often detectable months or years after the initiation of AD pathogenesis. Therefore, early detectable concentrations of cis pT231-tau, changes in cis pT231-tau levels, and the ratio of cis pT231-tau to trans pT231-tau in body fluids and blood from normal and AD patients might be better and more standardized biomarkers for early diagnosis.

To date, AD remains incurable, and a pool of issues remains to be solved. First and foremost, whether Aβ pathology occurs first and induces tau-related pathology, or vice versa, is still controversial. The answer to this question may influence the efficacy of targeted therapies specific for Aβ or tau. Moreover, available therapeutic strategies primarily focus on slowing down the progression of cognitive decline and neurodegeneration rather than targeting essential pathways (Pastorino et al., 2013). Furthermore, the administration of drugs at late stages due to the lack of early diagnosis may dramatically attenuate the efficacy since AD usually takes more than a decade to develop. Notably, the discovery of the Pin1-catalyzed cis/trans isomerization of phosphorylated S/T-P motifs in tau and APP and cis pT231-tau, but not trans pT231-tau, as an early and potent driver in MCI and AD, offers an attractive and promising therapeutic strategy for AD. A generation of mouse monoclonal antibodies specific for cis pT231-tau has been developed and shown to eliminate pathologic cis pT231-tau and prevent tau-related pathology development and spread (Kondo et al., 2015; Albayram et al., 2017). Importantly, immunotherapy employing this strategy specifically aims at the earliest possible pathogenic form of tau rather than the physiological trans form of pT231-tau with normal functions in AD (Kondo et al., 2015). Thus, further humanization of the cis pT231-tau antibody is conducive to developing novel therapeutic strategies for AD.

Because Pin1 plays an important role in preventing tau-related and Aβ pathologies in AD, the upregulation and/or activation of Pin1 could be a viable strategy for AD treatment. However, Pin1 overexpression contributes to a number of cancers, eliminating the possibility of direct administration (Zhou and Lu, 2016). Aberrant Pin1 elevation has been shown to be involved in many signaling events such as cell cycle coordination, chromosome instability, proliferation, migration, metastasis, and apoptosis in cancer (Zhou and Lu, 2016). Indeed, Pin1 is known to activate 56 oncogenes and inactivate 26 tumor suppressors by regulating their activity, protein interaction, stability, and cellular localization (Cheng and Tse, 2019; Yu et al., 2020). Pin1 overexpression in mammary gland induces chromosome instability and leads to breast cancer development and Pin1 ablation effectively prevents tumorigenesis by overexpressing Neu in animal models (Wulf et al., 2004; Suzui et al., 2006). Therefore, direct Pin1 activation in brain might cause malignant brain tumor. If we could specifically deliver Pin1 activator to neurons, it might be useful because neurons do not divide or proliferate. In addition, therapeutic strategies targeting Pin1 also focus on the upstream regulators of Pin1 such as DAPK1 or targets such as cis or trans pT231-tau. Indeed, the inhibition of DAPK1 has been shown to attenuate tau hyperphosphorylation and Aβ production (Kim et al., 2014, 2016, 2019; You et al., 2017; Chen et al., 2019). Thus, Pin1-related therapeutic strategies might be valuable in the treatment of AD.

CONCLUSION

The peptidyl-prolyl cis/trans isomerase Pin1 is a crucial regulator that is implicated in a wide variety of physiological and pathological activities. The deregulation of Pin1 expression and/or activity is associated with the development of cancer.
and neurodegeneration, including AD. Interestingly, Pin1 regulates the conformational change of both tau and APP and has protective effects against tau-related and Aβ pathology, suggesting that Pin1 might be a novel and promising candidate for exploring the molecular mechanisms, diagnosis, and treatment of AD.

The availability of drug candidates largely depends on animal models. Currently, many types of single or biogenic Tg mice are broadly used to study tau-related and Aβ pathologies; however, these mice fail to recapitulate all aspects of human AD. Pin1 KO mice develop both tau-related and Aβ pathologies in an age-dependent manner by employing endogenous tau and APP proteins, providing an attractive in vivo model for AD research and drug testing. Novel therapeutic strategies such as cis pT231-tau antibodies that target conformation-specific phosphorylated tau or small molecules such as DAPK1 inhibitors might provide effective treatment for human AD. However, many questions, including how to regulate Pin1 levels due to its dual roles in cancer and AD, how to overcome the blood-brain barrier for antibody treatment, and how to validate a suitable time for drug administration in the early stage of AD, remain to be answered before clinical validation. Moreover, Pin1 has been shown to lead different direction of tau phosphorylation and APP processing depending on cellular context. More research is urgently needed to illuminate the underlying roles of Pin in the molecular regulation, early diagnosis, potential treatment, and possible prevention of AD.

**AUTHOR CONTRIBUTIONS**

This review manuscript was conceptualized by LW and TL. YZ prepared figures. DC professionally edited the manuscript. LW, YZ, and TL wrote the manuscript.

**FUNDING**

This study was supported by grants from the Startup Fund for Scientific Research, Fujian Medical University (2016QH004 and 2017Q1003), Fujian Provincial Project of Education and Science for Young and Middle-aged Teachers (JAT170211 and JAT170216), the National Natural Science Foundation of China (81970993), the Natural Science Foundation of Fujian Province (2019J01297), the Medical Innovation Grant of Fujian Province (2019-CX-36), Fujian Medical University (XRCZX2017019), and the Alzheimer's Disease Research Program of the Alzheimer's Association (AARG-17-528817).

**REFERENCES**

Ahuja, P., Cantrelle, F. X., Huvent, I., Hanouille, X., Lopez, J., Smet, C., et al. (2016). Proline conformation in a functional tau fragment. *J. Mol. Biol.* 428, 79–91. doi: 10.1016/j.jmb.2015.11.023

Akiyama, H., Shin, R. W., Uchida, C., Kitamoto, T., and Uchida, T. (2005). Pin1 promotes production of Alzheimer's amyloid beta from beta-cleaved amyloid precursor protein. *Biochem. Biophys. Res. Commun.* 336, 521–529. doi: 10.1016/j.bbrc.2005.08.130

Albayram, O., Angeli, P., Bernstein, E., Baxley, S., Gao, Z., Lu, K. P., et al. (2018). Targeting prion-like cis phosphorylated tau pathology in neurodegenerative diseases. *J. Alzheimer's Dis. Parkinsonism* 8:443. doi: 10.4172/2161-0460.1000443

Albayram, O., Herbert, M. K., Kondo, A., Tsai, C. Y., Baxley, S., Lian, X., et al. (2016). Function and regulation of tau conformations in the development and treatment of traumatic brain injury and neurodegeneration. *Cell Biosci.* 6:59. doi: 10.1186/s13578-016-0124-4

Albayram, O., Kondo, A., Mannix, R., Smith, C., Tsai, C. Y., Li, C., et al. (2017). Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. *Nat. Commun.* 8:1000. doi: 10.1038/s41467-017-01068-4

Alonso, A. C., Zaidi, T., Grundke-Iqbal, I., and Iqbal, K. (1994). Role of abnormally Ballatore, C., Lee, V. M., and Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nat. Rev. Neurosci.* 8, 663–672. doi: 10.1038/nrn2194

Behrni, C. D., Bailey, M. L., Bateman, K. S., Hamilton, K. S., Wahl, L. M., Brandi, C. J., et al. (2003). Functionally important residues in the peptidyl-prolyl isomerase Pin1 revealed by unigenic evolution. *J. Mol. Biol.* 365, 1143–1162. doi: 10.1016/j.jmb.2006.10.078

Binder, L. I., Guillotet-Bongaarts, A. L., Garcia-Sierra, F., and Berry, R. W. (2005). Tau, tangles, and Alzheimer's disease. *Biochem. Biophys. Acta* 1739, 216–223.

Blair, L. J., Baker, J. D., Sabbagh, J. J., and Dickey, C. A. (2015). The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease. *J. Neurochem.* 133, 1–13. doi: 10.1111/jnc.13033

Bramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., and Lee, V. M. (1993). Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. *Neuron* 10, 1089–1099. doi: 10.1016/0896-6273(93)90057-x

Bulbarelli, A., Lonati, E., Cazzania, E., Gregori, M., and Masserini, M. (2009). Pin1 affects Tau phosphorylation in response to Abeta oligomers. *Mol. Cell Neurosci.* 42, 75–80. doi: 10.1016/j.mcn.2009.06.001

Butterfield, D. A. (2019). Phosphoproteomics of Alzheimer disease brain: Insights into altered brain protein regulation of critical neuronal functions and their contributions to subsequent cognitive loss. *Biochem. Biophys. Acta Mol. Basis Dis.* 1865, 2031–2039. doi: 10.1016/j.bbadis.2018.08.035

Butterfield, D. A., Poon, H. F., St Clair, D., Keller, J. N., Pierce, W. M., Klein, J. B., et al. (2006). Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. *Neurobiol. Dis.* 22, 223–232. doi: 10.1016/j.nbd.2005.11.002

Cai, H., Wang, Y., Mccarthy, D., Wen, H., Borchelt, D. R., Price, D. L., et al. (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. *Nat. Neurosci.* 4, 233–234. doi: 10.1038/85064

Cao, L., Wang, F., Ge, H., Wu, P. C., Qu, P., Chen, G. H., et al. (2013). Functionally important residues in the peptidyl-prolyl isomerase Pin1 revealed by unigenic evolution. *J. Mol. Biol.* 365, 1143–1162. doi: 10.1016/j.jmb.2006.10.078

Cao, L., Wang, F., Ge, H., Wu, P. C., Qu, P., Chen, G. H., et al. (2013). Pin1 regulates the conformational change of both tau and APP and has protective effects against tau-related and Aβ pathology, suggesting that Pin1 might be a novel and promising candidate for exploring the molecular mechanisms, diagnosis, and treatment of AD.

The availability of drug candidates largely depends on animal models. Currently, many types of single or biogenic Tg mice are broadly used to study tau-related and Aβ pathologies; however, these mice fail to recapitulate all aspects of human AD. Pin1 KO mice develop both tau-related and Aβ pathologies in an age-dependent manner by employing endogenous tau and APP proteins, providing an attractive in vivo model for AD research and drug testing. Novel therapeutic strategies such as cis pT231-tau antibodies that target conformation-specific phosphorylated tau or small molecules such as DAPK1 inhibitors might provide effective treatment for human AD. However, many questions, including how to regulate Pin1 levels due to its dual roles in cancer and AD, how to overcome the blood-brain barrier for antibody treatment, and how to validate a suitable time for drug administration in the early stage of AD, remain to be answered before clinical validation. Moreover, Pin1 has been shown to lead different direction of tau phosphorylation and APP processing depending on cellular context. More research is urgently needed to illuminate the underlying roles of Pin in the molecular regulation, early diagnosis, potential treatment, and possible prevention of AD.

**AUTHOR CONTRIBUTIONS**

This review manuscript was conceptualized by LW and TL. YZ prepared figures. DC professionally edited the manuscript. LW, YZ, and TL wrote the manuscript.

**FUNDING**

This study was supported by grants from the Startup Fund for Scientific Research, Fujian Medical University (2016QH004 and 2017Q1003), Fujian Provincial Project of Education and Science for Young and Middle-aged Teachers (JAT170211 and JAT170216), the National Natural Science Foundation of China (81970993), the Natural Science Foundation of Fujian Province (2019J01297), the Medical Innovation Grant of Fujian Province (2019-CX-36), Fujian Medical University (XRCZX2017019), and the Alzheimer's Disease Research Program of the Alzheimer's Association (AARG-17-528817).
function in Alzheimer's disease. *Neurobiol. Dis.* 76, 13–23. doi: 10.1016/j.nbd.2014.12.027

Chen, D., Wang, L., and Lee, T. H. (2020). Post-translational Modifications of the Peptidyl-Prolyl Isomerase Pin1. *Front. Cell Dev. Biol.* 8:129. doi: 10.3389/fcell.2020.00129

Chen, D., Zhou, X. Z., and Lee, T. H. (2019). Death-associated protein kinase 1 as a promising drug target in cancer and Alzheimer's disease. *Recent Pat. Anticancer Drug Discov.* 14, 144–157. doi: 10.2174/157492814666181218170257

Cheng, C. W., and Tse, E. (2019). Targeting PIN1 as a therapeutic approach for hepatocellular carcinoma. *Front. Cell Dev. Biol.* 7:639. doi: 10.3389/fcell.2019.00369

Cohen, P. (1982). The role of protein phosphorylation in neural and hormonal control of cellular activity. *Nature* 296, 613–620. doi: 10.1038/296613a0

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261, 921–923. doi: 10.1126/science.8346443

Cortes-Hernandez, P., and Dominguez-Ramirez, L. (2017). Role of cis-trans proline isomerization in the function of pathogenic enterobacterial periplasmic binding proteins. *PLoS One* 12:e0188935. doi: 10.1371/journal.pone.0188935

Dakson, A., Yokota, O., Esiri, M., Bigio, E. H., Horan, M., Pendleton, N., et al. (2014). Cleavage of amyloid beta peptide during constitutive processing of V717F beta-amyloid precursor protein. *Nature* 373, 523–527. doi: 10.1038/373523a0

Geschwind, D. H. (2003). Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? *Neuron* 40, 457–460. doi: 10.1016/s0896-6273(03)00681-0

Giusti, J., Chambraud, B., Sardin, E., Douanne, O., Guillemeau, K., Nakatani, K., et al. (2014). Immunophilin FKBP25 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy. *Proc. Natl. Acad. Sci. U.S.A.* 111, 4584–4589. doi: 10.1073/pnas.140265111

Giusti, J., Guillemeau, K., Douanne, O., Sardine, E., Huvent, I., Schmitt, A., et al. (2015). The FK506-binding protein FKBP25 in vitro induces aggregation of truncated Tau forms with prion-like behavior. *FASEB J.* 29, 3171–3181. doi: 10.1096/fj.14-268243

Giusti, J., Sineus, M., Sardin, E., Douanne, O., Panchal, M., Szadovitch, V., et al. (2012). Decrease of the immunophilin FKBP25 accumulation in human brains of Alzheimer's disease and FTDP-17. *J. Alzheimers Dis.* 29, 471–483. doi: 10.3233/JAD-2011-111985

Goedert, M., and Spillantini, M. G. (2006). A century of Alzheimer's disease. *Science* 314, 777–781.

Goedert, M., Spillantini, M. G., Cairns, N. J., and Crowther, R. A. (1992). Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. *Neuron* 8, 159–168. doi: 10.1016/0896-6273(92)90117-v

Gotz, J., and Ittner, L. M. (2008). Animal models of Alzheimer’s disease and frontotemporal dementia. *Nat. Rev. Neurosci.* 9, 532–544. doi: 10.1038/200900402

Guo, L., Du, H., Yan, S., Wu, X., McKhann, G. M., Chen, J. X., et al. (2013). Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimer’s neurons. *PLoS One* 8:e54914. doi: 10.1371/journal.pone.0054914

Halliwell, B. (2006). Oxidative stress and neurodegeneration: where are we now? *J. Neurochem.* 97, 1634–1658. doi: 10.1111/j.1471-4159.2006.03907.x

Hampel, H., Buerger, K., Kohnken, R., Teipel, S. J., Zinkowski, R., Moeller, H. J., et al. (2001). Tracking of Alzheimer’s disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. *Ann. Neurol.* 49, 545–546.

Han, C. H., Lu, J., Wei, Q., Bondy, M. L., Brewster, A. M., Yu, T. K., et al. (2010). The functional promoter polymorphism (~842G→C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. *Breast Cancer Res. Treat.* 122, 243–249. doi: 10.1007/s10549-009-0682-9

Hanes, S. D., Shank, P. R., and Bostian, K. A. (1989). Sequence and mutational analysis of ESS1, a gene essential for growth in Saccharomyces cerevisiae. *Yeast* 5, 55–72. doi: 10.1002/yea.3200510508

Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. *Science* 297, 335–356. doi: 10.1126/science.1072994

Holzer, M., Gartner, U., Stobe, A., Hartig, W., Gruschka, H., Bruckner, M. K., et al. (2002). Inverse association of Pin1 and tau accumulation in Alzheimer’s disease hippocampus. *Acta Neuropathol.* 104, 471–481. doi: 10.1007/s00401-002-0581-1

Hoover, C., Klicic, R., and Lovestone, S. (2008). The GSK3 hypothesis of Alzheimer’s disease. *J. Neurochem.* 104, 1433–1449. doi: 10.1111/j.1471-4159.2007.05194.x

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. *Science* 274, 99–102. doi: 10.1126/science.274.5284.99

Huq, A. J., Fransquet, P., Laws, S. M., Ryan, J., Sebra, R., Masters, C. L., et al. (2019). Genetic resilience to Alzheimer’s disease in APOE epsilon4 homozygotes: a systematic review. *Alzheimers Dement* 15, 1612–1623. doi: 10.1016/j.jalz.2019.05.011

Hurtado, D. E., Molina-Porcel, L., Carroll, J. C., Macdonald, C., Aboagye, A. K., Trojanowski, J. Q., et al. (2012). Selectively silencing GSK-3 isoforms reduces...
plagues and tangles in mouse models of Alzheimer’s disease. *J. Neurosci.* 32, 7392–7402. doi: 10.1523/JNEUROSCI.0889-12.2012

Iqbal, K., Liu, F., and Gong, C. X. (2016). Tau and neurodegenerative disease: the story so far. *Nat. Rev. Neuro.*** 12, 15–27. doi: 10.1038/nrneurol.2015.225

Iqbal, K., Liu, F., Gong, C. X., Alonso, A., Chen, D., and Grundke-Iqbal, I. (2009). Mechanisms of tau-induced neurodegeneration. *Acta Neuropathol.* 118, 53–69.

Ittner, L. M., and Gotz, J. (2011). Amyloid-beta and tau—a toxic pact de deux in Alzheimer’s disease. *Nat. Rev. Neurosci.* 12, 65–72. doi: 10.1038/nrn2967

Jiang, H., Guo, W., Liang, X., and Rao, Y. (2005). Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK3-beta and its upstream regulators. *Cell* 120, 123–135. doi: 10.1016/j.cell.2004.12.033

Kim, B. M., You, M. H., Chen, C. H., Lee, S., Hong, Y., Hong, Y., et al. (2014). Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. *Cell Death Dis.* 5:e1237. doi: 10.1038/cddis.2014.216

Kim, B. M., You, M. H., Chen, C. H., Suh, J., Tanzi, R. E., and Ho Lee, T. (2016). Inhibition of death-associated protein kinase 1 attenuates the phosphorylation and amyloidogenic processing of amyloid precursor protein. *Hum. Mol. Genet.* 25, 2498–2513. doi: 10.1093/hmg/ddw114

Kim, N., Chen, D., Zhou, X. Z., and Lee, T. H. (2019). Death-associated protein kinase 1 phosphorylation in neuronal cell death and Neurodegenerative disease. *Int. J. Mol. Sci.* 20:3131. doi: 10.3390/ijms20133131

Kimura, T., Tsutsumi, K., Taoka, M., Saito, T., Masuda-Suzukake, M., Ishiguro, K., et al. (2013). Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk)-dependent Alzheimer phosphorylation sites. *J. Biol. Chem.* 288, 7968–7977. doi: 10.1074/jbc.M112.433326

Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C. H., et al. (2015). Antibody against early driver of neurodegeneration cis-P-tau blocks brain injury and tauopathy. *Nature* 523, 431–436. doi: 10.1038/nature14658

Koo, E. H., and Squazzo, S. L. (1994). Evidence that production and release of amyloid beta-protein involves the endocytic pathway. *J. Biol. Chem.* 269, 17386–17389.

Kutter, S., Eichner, T., Deaconescu, A. M., and Kern, D. (2016). Regulation of microtubule assembly by Tau and not by Pin1. *J. Mol. Biol.* 428, 1742–1759. doi: 10.1016/j.jmb.2016.03.010

Lambert, J. C., Benserain, F., Chapuis, J., Cottel, D., and Amouyel, P. (2006). Association study of the PIN1 gene with Alzheimer’s disease. *Biochem. Soc. Trans.* 38, 1006–1011. doi: 10.1042/BST0381006

Landrieu, I., Smet-Nocca, C., Amniai, L., Louis, J. V., Wieruszeski, J. M., Goris, J., et al. (2013). Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk)-dependent Alzheimer phosphorylation sites. *J. Biol. Chem.* 288, 7968–7977. doi: 10.1074/jbc.M112.433326

Liou, Y. C., Sun, A., Ryo, A., Zhou, X. Z., Yu, Z. X., Huang, H. K., et al. (2003). Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. *Nature* 424, 556–561. doi: 10.1038/nature01832

Lippens, G., Landrieu, I., and Smet, C. (2007). Molecular mechanisms of the phospho-dependent prolyl cis/trans isomerase Pin1. *FEBS** J.* 274, 5211–5222. doi: 10.1111/j.1742-4658.2007.00657.x

Lippens, G., Landrieu, I., Smet, C., Huvent, I., Gandhi, N. S., Gigant, B., et al. (2016). NMR Meets Tau: Insights into Its Function and Pathology. *Biomolecules* 6:28. doi: 10.3390/biom6020028

Long, J. M., and Holtzman, D. M. (2019). Alzheimer disease: an update on pathobiology and treatment strategies. *Cell* 179, 312–339. doi: 10.1016/j.cell.2019.09.001

Lovestone, S., Reynolds, C. H., Lattimer, D., Davis, D. R., Anderton, B. H., Gallo, J. M., et al. (1994). Alzheimer’s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. *Curr. Biol.* 4, 1077–1086. doi: 10.1016/S0960-9822(00)00246-3

Lu, J., Yang, L., Zhao, H., Liu, B., Li, Y., Wang, H., et al. (2011). The polymerorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations. *Hum. Mutat.* 32, 1299–1308. doi: 10.1002/humu.21574

Lu, K. P. (2004). Pinning down cell signaling, cancer and Alzheimer’s disease. *Trends Biochem. Sci.* 29, 200–209. doi: 10.1016/j.tibs.2004.02.002

Lu, K. P., Finn, G., Lee, T. H., and Nicholson, L. K. (2007). Prolyl cis-trans isomerization as a molecular timer. *Nat. Chem. Biol.* 3, 619–629. doi: 10.1038/nchembio.2007.35

Lu, K. P., Hanes, S. D., and Hunter, T. (1996). A human peptidyl-prolyl isomerase essential for regulation of mitosis. *Nature* 380, 544–547. doi: 10.1038/380544a0

Lu, K. P., Kondo, A., Albayram, O., Herbert, M. K., Liu, H., and Zhou, X. Z. (2016). Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. *JAMA Neurol.* 73, 1356–1362. doi: 10.1001/jamaneurol.2016.2027

Lu, K. P., Liou, Y. C., and Vincent, I. (2003). Proline-directed phosphorylation and isomerization in mitotic regulation and in Alzheimer’s Disease. *Bioessays* 25, 174–181. doi: 10.1002/bies.10223

Lu, K. P., Liu, Y. C., and Zhou, X. Z. (2002). Pinning down proline-directed phosphorylation signaling. *Trends Cell Biol.* 12, 164–172. doi: 10.1016/S0962-8924(02)00253-5

Lu, K. P., and Zhou, X. Z. (2007). The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. *Nat. Rev. Mol. Cell Biol.* 8, 904–916. doi: 10.1038/nrm2261

Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P., and Lu, K. P. (1999a). The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. *Nature* 399, 784–788. doi: 10.1038/21650

Lu, P. J., Zhou, X. Z., Shen, M., and Lu, K. P. (1999b). Function of WW domains as phosphoserine- or phosphothreonine-binding modules. *Science* 283, 1325–1328. doi: 10.1126/science.283.5406.1325

Lu, Y., Huang, G. L., Pu, X. X., He, Y. X., Li, B. B., Liu, X. Y., et al. (2013). Association between PIN1 promoter polymorphisms and risk of nasopharyngeal carcinoma. *Mol. Biol. Rep.* 40, 3777–3782. doi: 10.1007/s11033-012-2454-6

Luna-Munoz, J., Chavez-Macias, L., Garcia-Sierra, F., and Mena, R. (2007). Earlier stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer’s disease. *J. Alzheimers Dis.* 11, 174–181. doi: 10.3233/jad-2007-12410

Ma, S. L., Pastirino, L., Zhou, X. Z., and Lu, K. P. (2012a). Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3beta (GSK3beta) activity: novel mechanism for Pin1 to protect
against Alzheimer disease. J. Biol. Chem. 287, 6969–6973. doi: 10.1074/jbc.C111.298596
Ma, S. L., Tang, N. L., Tam, C. W., Liu, V. W., Lam, L. C., Chiu, H. F., et al. (2012b). A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease. Neurobiol. Aging. 33, 804–813. doi: 10.1016/j.neurobiolaging.2011.05.018
Markesbery, W. R. (1997). Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol. Med. 23, 134–147.
Matsuo, E. S., Shin, R. W., Billingsley, M. L., Van Devoorde, A., O'Connor, M., Trojanowski, J. Q., et al. (1994). Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13, 989–1002. doi: 10.1016/0896-6273(94)90264-x
Mckhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R. Jr., Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263–269. doi: 10.1016/j.jalz.2011.03.005
Mu, Y., and Gage, F. H. (2011). Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol. Neurodegener. 6:85. doi: 10.1186/1750-1326-6-85
Nakamura, K., Greenwood, A., Binder, L., Bigio, E. H., Denial, S., Nicholson, L., et al. (2012). Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 149, 232–244. doi: 10.1016/j.cell.2012.02.016
Nelson, P. T., Alafuzzo, L., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362–381. doi: 10.1097/NEN.0b013e3182510878
Nestler, E. J., and Greengard, P. (1983). Protein phosphorylation in the brain. Frontiers in Cell and Developmental Biology | www.frontiersin.org 11 May 2020 Volume 8 Article 355 14
Wang, J., Gu, B. J., Masters, C. L., and Wang, Y. J. (2017). A systemic view of Alzheimer disease hippocampus: a redox proteomics analysis. Neurobiol. Aging 27, 918–925.
doi: 10.1016/j.neurobiolaging.2005.05.005

Suzuki, T., and Nakaya, T. (2008). Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J. Biol. Chem. 283, 29633–29637.
doi: 10.1074/jbc.R80003200

Wulf, G., Finn, G., Suizu, F., and Lu, K. P. (2004). Modeling breast cancer in vivo: revealing an essential role of Pin1 in tumorigenesis. EMBO J. 23, 3397–3407.
doi: 10.1038/sj.emboj.7600323

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wang, Zhou, Chen and Lee. This is an open-access article published under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.